Your browser doesn't support javascript.
loading
Tranexamic acid is safe to use following mild-to-moderate traumatic brain injury.
Cook, Rob; Lyon-Maris, Johnny; Martin, Rosie.
Afiliación
  • Cook R; Bazian, Economist Intelligence Unit healthcare, London, UK.
  • Lyon-Maris J; Wessex Institute, University of Southampton, Southampton, UK.
  • Martin R; Bazian, Economist Intelligence Unit healthcare, London, UK.
BMJ ; 368: m514, 2020 03 11.
Article en En | MEDLINE | ID: mdl-32161036
The studyThe CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019;394:1713-23.This trial was funded by NIHR Health Technology Assessment Programme (project number 14/190/01), JP Moulton Charitable Trust, Department of Health and Social Care, Department for International Development, Global Challenges Research Fund, Medical Research Council, and the Wellcome Trust (Joint Global Health Trials scheme).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000870/tranexamic-acid-following-mild-to-moderate-traumatic-brain-injury-is-safe-and-reduces-deaths.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Lesiones Traumáticas del Encéfalo / Antifibrinolíticos Tipo de estudio: Clinical_trials / Health_technology_assessment Límite: Humans Idioma: En Revista: BMJ Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Lesiones Traumáticas del Encéfalo / Antifibrinolíticos Tipo de estudio: Clinical_trials / Health_technology_assessment Límite: Humans Idioma: En Revista: BMJ Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido